Searched for:
(1 - 4 of 4)
document
van der Ploeg, C.P.B. (author), Grevinga, M. (author), Eekhout, I. (author), Vlasblom, E. (author), Lanting, C.I. (author), van Minderhout, H.M. (author), Dijk-van der Poel, J. (author), van den Akker-van Marle, M.E. (author), Verkerk, P.H. (author)
Background: Little is known about costs and effects of vision screening strategies to detect amblyopia. Aim of this study was to compare costs and effects of conventional (optotype) vision screening, photoscreening or a combination in children aged 3-6 years. Methods: Population-based, cross-sectional study in preventive child health care in The...
article 2021
document
van der Ploeg, C.P.B. (author), Grevinga, M. (author), Eekhout, I. (author), Vlasblom, E. (author), Lanting, C.I. (author), van Minderhout, H.M. (author), Dijk-van der Poel, J. (author), van den Akker-van Marle, M.E. (author), Verkerk, P.H. (author)
Comment on the article: Costs and effects of conventional vision screening and photoscreening in the Dutch preventive child health care system. We thank professor Simonsz for his comments, since it gives us the opportunity to clarify some of our findings. Indeed, with the price for the photoscreening device of €2.29 per child as calculated in...
article 2021
document
van der Ploeg, C.P.B. (author), Blom, M. (author), Bredius, R.G.M. (author), van der Burg, M. (author), Schielen, P.C.J.I. (author), Verkerk, P.H. (author), van den Akker-van Marle, M.E. (author)
Severe combined immunodeficiency (SCID) is a condition that often results in severe infections and death at young age. Early detection shortly after birth, followed by treatment before infections occur, largely increases the chances of survival. As the incidence of SCID is low, assessing cost-effectiveness of adding screening for SCID to the...
article 2019
document
van den Akker-van Marle, M.E. (author), Gurwitz, D. (author), Detmar, S.B. (author), Enzing, C.M. (author), Hopkins, M.M. (author), Gutierrez De Mesa, E. (author), Ibarreta, D. (author), TNO Kwaliteit van Leven (author)
Only a few studies have addressed the cost-effectiveness of pharmacogenetics interventions in healthcare. Lack of health economics data on aspects of pharmacogenetics is perceived as one of the barriers hindering its implementation for improving drug safety. Thus, a recent Institute for Prospective Technological Studies (IPTS) study, entitled ...
article 2006
Searched for:
(1 - 4 of 4)